Roehrborn CG, Albertsen P, Stokes ME, Black L, Benedict A. First-year costs of treating prostate cancer: estimates from SEER-Medicare data. Prostate Cancer Prostatic Dis 2009. In press.

[1]  J. Hanley,et al.  A statistical evaluation of rules for biochemical failure after radiotherapy in men treated for prostate cancer. , 2009, International Journal of Radiation Oncology, Biology, Physics.

[2]  Gerardo Fernandez,et al.  Personalized prediction of tumor response and cancer progression on prostate needle biopsy. , 2009, The Journal of urology.

[3]  T. Wilt,et al.  Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. , 2009, The Journal of urology.

[4]  T. Wilt,et al.  Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Peter C Albertsen,et al.  The treatment paradigm shifts again on prostate cancer. , 2009, European urology.

[6]  P. Albertsen.  A challenge to contemporary management of prostate cancer , 2009, Nature Clinical Practice Urology.

[7]  P. Albertsen,et al.  Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen era. , 2008, The Journal of urology.

[8]  J. Stanford,et al.  Screening, Treatment, and Prostate Cancer Mortality in the Seattle Area and Connecticut: Fifteen-year Follow-up , 2008, Journal of General Internal Medicine.

[9]  Dirk F Moore,et al.  Survival following primary androgen deprivation therapy among men with localized prostate cancer. , 2008, JAMA.

[10]  F. Hamdy,et al.  Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. , 2008, The Lancet. Oncology.

[11]  P. Albertsen.  Should men over the age of 65 years receive PSA screening? Argument against , 2008, Nature Clinical Practice Urology.

[12]  James A Hanley,et al.  Detecting trends in noisy data series: application to biomarker series. , 2008, American journal of epidemiology.

[13]  P. Albertsen.  The face of high risk prostate cancer , 2008, World Journal of Urology.

[14]  James A Hanley,et al.  Hierarchical changepoint models for biochemical markers illustrated by tracking postradiotherapy prostate-specific antigen series in men with prostate cancer. , 2008, Annals of epidemiology.

[15]  F. Hamdy,et al.  Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975–2004 , 2008, BJU international.

[16]  P. Albertsen.  Should men with low-risk, localized prostate cancer choose active surveillance or undergo a robotic prostatectomy? , 2008, Current urology reports.

[17]  L. Mucci,et al.  Screening for bladder cancer: Theoretical and practical issues in considering the treated and untreated natural history of the various forms of the disease , 2008, Scandinavian journal of urology and nephrology. Supplementum.

[18]  P. Albertsen.  Predicting survival for men with clinically localized prostate cancer , 2008, Cancer.

[19]  J. Verne,et al.  Patient outcomes and length of hospital stay after radical prostatectomy for prostate cancer: analysis of Hospital Episodes Statistics for England , 2007, BJU international.

[20]  P. Albertsen,et al.  Competing risks for patients with localized prostate cancer. , 2007, Journal of the National Cancer Institute.

[21]  P. Albertsen.  What do we really know about prostate cancer? , 2007, European urology.

[22]  P. Albertsen.  Commentary: occult prostate cancer--imposter or the real deal? , 2007, International journal of epidemiology.

[23]  James A Hanley,et al.  13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. , 2007, The Journal of urology.

[24]  P. Albertsen.  Does radical prostatectomy provide a survival benefit as primary treatment for high-grade prostate cancer? , 2007, Nature Clinical Practice Urology.

[25]  Ziding Feng,et al.  5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. , 2005, The Journal of urology.